Dallas, Texas-based Vaxxinity, under the direction of CEO Mei Mei Hu, JD and Chief Medical Officer Ulo Palm, uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance”, or the body’s tendency to avoid attacking molecules within your own body. Traditional vaccine technologies have to date fallen short in attempts to achieve this due to insufficient responses and side effects. The platform has been scientifically validated, with billions of doses commercialized in animal health, and 6 human clinical trials successfully completed. UB-313 targets CGRP to fight migraines. Vaxxinity has initiated IND-enabling studies.